News
MSLE
8.66
+2.97%
0.25
Satellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $22
TipRanks · 6h ago
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding
TipRanks · 9h ago
Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned
NASDAQ · 10h ago
Satellos announces U.S. FDA cleared IND application for forazapadin
TipRanks · 10h ago
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
Benzinga · 10h ago
Weekly Report: what happened at MSLE last week (0914-0918)?
Weekly Report · 3d ago
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress
TipRanks · 09/15 11:30
Weekly Report: what happened at MSLE last week (0907-0911)?
Weekly Report · 09/14 09:14
Satellos Names Forazapadin As INN For Lead DMD Drug Candidate
NASDAQ · 09/09 11:53
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance
TipRanks · 09/09 11:28
Satellos assigns forazapadin name to SAT-3247
TipRanks · 09/09 11:16
Weekly Report: what happened at MSLE last week (0831-0904)?
Weekly Report · 09/07 09:13
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences
TipRanks · 09/01 11:31
Weekly Report: what happened at MSLE last week (0824-0828)?
Weekly Report · 08/31 09:14
LifeSci Capital Sticks to Their Buy Rating for Satellos Bioscience (MSLE)
TipRanks · 08/30 13:25
Buy Rating on Satellos Bioscience Highlights Transformative Potential of First-in-Class Oral DMD Therapy Ahead of Key 4Q26 Phase 2 Readouts
TipRanks · 08/25 10:27
Satellos initiated with an Outperform at LifeSci Capital
TipRanks · 08/25 10:20
Weekly Report: what happened at MSLE last week (0817-0821)?
Weekly Report · 08/24 09:14
Satellos: Buy Rating Reiterated as Phase 2 Progress Advances and $18 Price Target Remains Unchanged
TipRanks · 08/17 11:36
HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
Benzinga · 08/17 10:34
More
Webull provides a variety of real-time MSLE stock news. You can receive the latest news about Satellos Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About MSLE
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.